The core technology of GLPT is to provide promising dispersible tablet. The dispersible tablet of this invention has some advantages: easy formulation procedures and high solubility in water.
Background and unmet needs: Amoxicillin is a representative of β-lactam antibiotic substances and has efficacies on bacterial infection. Potassium clavulanate has a role of expanding anti-bacterial spectrum of amoxicillin as a function to inhibit β-lactamase. Mixture of amoxicillin/potassium clavulanate has been already developed and commercially utilized as a representative product, Augmentin®.
Discovery and Achievements: Mixture of amoxicillin/potassium clavulanate could be commercially purchased, which contains forms of tablet, dry syrup and injection. Among them, dry syrup was used in a form of suspension solution dissolved in a constant amount of water. However, dry syrup is prone to deterioration according to resuspended or storage conditions.
To overcome this problem, the GLPT has made intensive studies to develop an dispersible tablet for improving administration, formulation and solubility. As results, the GLPT has discovered the simple portable dispersible tablet of this invention with great stability, exact administration, easy formulation and high solubility in water.
The dispersible tablet of this invention was composed of disintegrant, filler, glydent, sweetner and pertume. The dispersible tablet of this invention was fabricated to be resuspended by disintegration in small amount of water within 1 min.
Karl Fisher method
Disintegration Time (sec)
Within 3 min